🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the fight against superbug strains of the infection, according to researchers.

An International Public Health Issue

Cases of gonorrhoea are increasing globally, with estimates suggesting over 82 million instances per year. Particularly high rates are seen in the African continent and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an important and timely advancement in the context of growing infection rates, increasing antimicrobial resistance and the extremely scarce therapeutic options presently on offer.”

Health officials are particularly alarmed about the increase in drug-resistant strains. The World Health Organization has designated it as a "priority pathogen". Recent surveillance revealed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Receive Approval

One new antibiotic, also known as a brand name, was approved by the US FDA in recent days for use against gonorrhoea. This disease can lead to significant complications, including infertility. Scientists hope that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, was also approved in close succession. This treatment, which is also used to treat urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin emerged from a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to see it through.

“This approval marks a huge turning point in the therapy of highly resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Testing Data and Global Access

According to findings published in a major medical journal, the new drug cured the vast majority of cases of the STI. This places it at an similar efficacy with the existing first-line therapy, which involves two antibiotics. The study enrolled over 900 participants from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the authority to make available and distribute the drug in many regions with limited resources.

Doctors directly involved have voiced optimism. Having a one-pill regimen of this kind is seen as a "game-changer" for public health efforts. This is deemed crucial to reduce the burden of the disease for individuals and to halt the transmission of untreatable gonorrhoea globally.